Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
Michelle K GreeneTing ChenEifion RobinsonNinfa L StraubingerCharlene MinxDarren K W ChanJun WangJames F BurrowsSandra Van SchaeybroeckJames R BakerStephen CaddickDaniel B LongleyDonald E MagerRobert M StraubingerVijay ChudasamaChristopher J ScottPublished in: British journal of cancer (2020)
Together, our findings offer renewed hope for CTX in PaCa therapy, demonstrating that it may be reformatted as a next-generation ADC and combined with a predictive modelling tool to guide successful translation.
Keyphrases
- wild type
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- klebsiella pneumoniae
- room temperature
- diffusion weighted imaging
- cancer therapy
- metastatic colorectal cancer
- locally advanced
- squamous cell carcinoma
- radiation therapy
- stem cells
- magnetic resonance imaging
- multidrug resistant
- rectal cancer
- ionic liquid